P53 and its molecular basis to chemoresistance in breast cancer
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: TP53 mutations have been associated with resistance to anthracyclines and mitomycin in breast cancer. This review examines the potential roles of different components in the p53 cascade with respect to drug resistance. AREAS COVERED: Literature was searched using the ISI Web and Pubmed. Considering p53 activation in response to genotoxic stress and phosphorylations by ataxia telangiectasia mutated/ataxia telangiectasia and radiation resistance gene 3 related (ATM/ATR). Downstream checkpoint proteins chk1 and chk2 are also considered to be of major importance. Recently, nonsense mutations in CHEK2, encoding the chk2 protein, were found to predict resistance to anthracycline therapy in some tumours harbouring wild-type TP53. While mouse double minute (MDM)2 or MDMX protein overexpression (often due to gene amplifications) may inactivate p53 in different tumour forms, so far, there is no evidence for MDM2 amplifications in breast cancers resistant to anthracyclines. The roles of p53 isoforms and p53-induced transcription of non-coding RNA remain to be defined. EXPERT OPINION: Disturbances affecting the 'p53 pathway(s)' may play a key role in chemoresistance in cancer. Although TP53 is not a clinical marker for drug resistance, like other genes (such as breast cancer associated 1/2 (BRCA1/2)) it may be considered a 'beacon' identifying critical gene cascades.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Direct Activation of Bax by p53 Mediates Mitochondrial Membrane Permeabilization and Apoptosis
Chipuk, J. E., Kuwana, T., Bouchier-Hayes, L., Droin, N. M., Newmeyer, D. D., Schuler, M., & Green, D. R. (2004) · Science · doi:10.1126/science.1092734 · Cited by 2,108 · cited 1×
“Yet, while genes like p53 up-regulated modulator of apoptosis (PUMA) and others have been associated with apoptosis in experimental systems (reviewed in [10]), the in vivo role of these genes, versus nontranscriptional gene activation (the ‘B cell leukemia 2 (bcl-2) pathway’) remains obscure [11,12].”
BackgroundCell cycle checkpoint signaling through the ATM and ATR kinases
Abraham, R. T. (2001) · Genes & Development · doi:10.1101/gad.914401 · Cited by 1,966
Dulić, V., Kaufmann, W. K., Wilson, S. J., Tisty, T. D., Lees, E., Harper, J. W., Elledge, S. J., & Reed, S. I. (1994) · Cell · doi:10.1016/0092-8674(94)90379-4 · Cited by 1,465 · cited 1×
“Transcriptional activation of the cyclin-dependent kinase inhibitor 1A (CDKN1A) gene (coding for p21 and p21B) by p53 is well known to play a key role in growth arrest [8,9].”
BackgroundRegulating the p53 pathway: in vitro hypotheses, in vivo veritas
Toledo, F., & Wahl, G. M. (2006) · Nature reviews. Cancer · doi:10.1038/nrc2012 · Cited by 1,286
Bond, G. L., Hu, W., Bond, E. E., Robins, H., Lutzker, S. G., Arva, N. C., Bargonetti, J., Bartel, F., Taubert, H., Wuerl, P., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.022 · Cited by 1,265 · cited 1×
“The first, SNP309G, has been found to enhance MDM2 transcription by strengthening the binding between the Sp1 transcription factor and the promoter [46] and, thus to increase the risk of breast and several other cancer forms [47].”
BackgroundThe ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis
Falck, J., Mailand, N., Syljuåsen, R. G., Bartek, J., & Lukas, J. (2001) · Nature · doi:10.1038/35071124 · Cited by 1,085 · cited 1×
“Notably, chk2 in addition plays a key role in a growth arrest pathway independent of p53 by activating Cdc25A and Cdc25C [23].”
BackgroundA Senescence Program Controlled by p53 and p16INK4a Contributes to the Outcome of Cancer Therapy
Schmitt, C. A., Fridman, J. S., Yang, M., Lee, S., Baranov, E., Hoffman, R. M., & Lowe, S. W. (2002) · Cell · doi:10.1016/s0092-8674(02)00734-1 · Cited by 1,050
p53 isoforms can regulate p53 transcriptional activity
Bourdon, J.-C., Fernandes, K., Murray-Zmijewski, F., Liu, G., Diot, A., Xirodimas, D. P., Saville, M. K., & Lane, D. P. (2005) · Genes & Development · doi:10.1101/gad.1339905 · Cited by 810 · cited 1×
“The TP53 gene expresses at least nine different splice variants, but we still have limited information regarding their potential roles in vivo [35].”
BackgroundATM and ATR: networking cellular responses to DNA damage
Shiloh, Y. (2001) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(00)00159-3 · Cited by 601 · cited 1×
“While ATM and its analogue ATR share several functions with respect to substrate phosphorylations [39] and there is evidence that these genes may overlap in a sequential manner [40], ATM is considered to be the main effector triggered by double-strand DNA breaks induced by ionizing radiation and drugs like the anthrac…”
BackgroundTranscription-independent pro-apoptotic functions of p53
Moll, U. M., Wolff, S., Speidel, D., & Deppert, W. (2005) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2005.09.007 · Cited by 468
Cited by
Molecular aspects of cancer cell resistance to chemotherapy
Rebucci, M., & Michiels, C. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.02.017 · Cited by 407
Peetla, C., Vijayaraghavalu, S., & Labhasetwar, V. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.004 · Cited by 289
APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells
Mohell, N., Alfredsson, J., Fransson, Å., Uustalu, M., Byström, S., Gullbo, J., Hallberg, A., Bykov, V. J. N., Björklund, U., & Wiman, K. G. (2015) · Cell Death & Disease · doi:10.1038/cddis.2015.143 · Cited by 183
Fransson, Å., Glaessgen, D., Alfredsson, J., Wiman, K. G., Bajalica-Lagercrantz, S., & Mohell, N. (2016) · Journal of Ovarian Research · doi:10.1186/s13048-016-0239-6 · Cited by 65
“Although it has been reported that inactivation of p53 can cause resistance to anthracyclines [36], the significance of p53 status for sensitivity to anthracyclines is less clear than its significance for sensitivity to platinum compounds.”
Background
Metadata
- Authors
- Knappskog, S., & Lønning, P. E.
- Venue
- Expert Opinion on Therapeutic Targets
- Publisher
- Informa UK Limited
- Published
- 2012-02-08
- Volume
- 16
- Issue
- sup1
- Pages
- S23-S30
- ISSN
- 1472-8222 (ISSN-L)
- 1744-7631
- OpenAlex
- W2170204650
- Cited by
- 74
- References
- 13
- FWCI
- 3.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: P53 and its molecular basis to chemoresistance in breast cancer. https://app.cochat.ai/papers/10.1517/14728222.2011.640322
- The paper
- Knappskog, S., & Lønning, P. E. (2012). P53 and its molecular basis to chemoresistance in breast cancer. Expert Opinion on Therapeutic Targets. https://doi.org/10.1517/14728222.2011.640322
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.